Inter-Slice Blood Flow and Magnetization Transfer Effects as A New Simultaneous Imaging Strategy

PLoS One. 2015 Oct 14;10(10):e0140560. doi: 10.1371/journal.pone.0140560. eCollection 2015.

Abstract

The recent blood flow and magnetization transfer (MT) technique termed alternate ascending/descending directional navigation (ALADDIN) achieves the contrast using interslice blood flow and MT effects with no separate preparation RF pulse, thereby potentially overcoming limitations of conventional methods. In this study, we examined the signal characteristics of ALADDIN as a simultaneous blood flow and MT imaging strategy, by comparing it with pseudo-continuous ASL (pCASL) and conventional MT asymmetry (MTA) methods, all of which had the same bSSFP readout. Bloch-equation simulations and experiments showed ALADDIN perfusion signals increased with flip angle, whereas MTA signals peaked at flip angle around 45°-60°. ALADDIN provided signals comparable to those of pCASL and conventional MTA methods emulating the first, second, and third prior slices of ALADDIN under the same scan conditions, suggesting ALADDIN signals to be superposition of signals from multiple labeling planes. The quantitative cerebral blood flow signals from a modified continuous ASL model overestimated the perfusion signals compared to those measured with a pulsed ASL method. Simultaneous mapping of blood flow, MTA, and MT ratio in the whole brain is feasible with ALADDIN within a clinically reasonable time, which can potentially help diagnosis of various diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Brain / blood supply
  • Cerebrovascular Circulation
  • Computer Simulation
  • Diagnostic Imaging / methods*
  • Humans
  • Image Processing, Computer-Assisted / methods
  • Meningioma / blood supply
  • Meningioma / diagnosis
  • Regional Blood Flow*

Grants and funding

This work was supported by a grant from National Research Foundation of Korea (NRF-2013R1A1A1061759 and NRF-2013M3A9B2076548) and Competitive Medical Research Fund of the UPMC (University of Pittsburgh Medical Center) Health System.